YUNGJIN PHARM. CO., LTD
Founded in 1962 and listed on the KOSPI in 1973, Yungjin Pharm is a KT&G Group pharmaceutical affiliate exporting antibiotic injectables and APIs and operating a CMO business.
Price
Change
Market cap
Products & technology
- Health drinksDrink-type pharmaceutical
- AntibioticsAntibiotic
- Nutritional infusion solutionsNutritional infusion
- Quasi-drugsQuasi-drug
Regulatory approvals
data.go.kr265 Korean MFDS drug approvals · 1973–2026 / 2 Korean MFDS device approvals · 2016
- MFDS drugAtoxetine Tab. 40mg(Atomoxetine Hydrochloride)2026-08-10Drug · Prescription · Approval202602321
- MFDS drugColmin nose Soft Cap.2026-02-04Drug · OTC · Notification202600316
- MFDS drugFULLMECOOL SUSPENSION FOR NEBULIZER2026-01-16Drug · Prescription · Approval202600153
- MFDS drugColmin-S Syrup2025-08-06Drug · OTC · Notification202502045
- MFDS drugColmin-S Tab.2025-06-26Drug · OTC · Notification202501581
- MFDS drugNeoblue5 inj.2025-06-18Drug · Prescription · Approval202501498
- MFDS drugNintebro Tab. 100mg2024-12-31Drug · Prescription · Approval202403105
- MFDS drugDemenduo tablet 10/20mg2024-12-23Drug · Prescription · Approval202403046
- MFDS drugNintebro Tab. 150mg2024-12-12Drug · Prescription · Approval202402952
- MFDS drugGinkamin Tab. 240mg2024-11-05Drug · OTC · Notification202402606
- MFDS drugAsrazole Cap. 100/5mg2024-09-30Drug · Prescription · Approval202402348
- MFDS drugImpac Speed Sol.2024-01-30Drug · OTC · Notification202400223
Show 68 more
- MFDS drugYungjindadu XR Tab. 10/500mg2023-06-21Drug · Prescription · Approval202301895
- MFDS drugDapflo Tab. 10mg2023-01-31Drug · Prescription · Approval202300414
- MFDS drugDapflo M SR Tab. 10/500mg2023-01-31Drug · Prescription · Approval202300428
- MFDS drugDapflo M SR Tab. 10/1000mg2023-01-31Drug · Prescription · Approval202300429
- MFDS drugRaceca Cap. 100mg(racecadotril)2023-01-18Drug · Prescription · Approval202300287
- MFDS drugYungjindaduXR10/1000mg2023-01-06Drug · Prescription · Approval202300152
- MFDS drugAripizin Tab. 1mg2022-12-23Drug · Prescription · Approval202204615
- MFDS drugTalimin SR Tab.2022-12-21Drug · Prescription · Approval202204557
- MFDS drugAripizin Tab. 2mg2022-12-07Drug · Prescription · Approval202204409
- MFDS drugYungJin Olanzapine Tablets 10mg2022-09-19Drug · Prescription · Approval202203600
- MFDS drugYungJin Olanzapine Tablets 5mg2022-09-19Drug · Prescription · Approval202203601
- MFDS drugTeliptin M SR Tab. 20/1000mg2022-07-01Drug · Prescription · Approval202202704
- MFDS drugTeliptin M SR Tab. 10/500mg2022-07-01Drug · Prescription · Approval202202705
- MFDS drugTeliptin M SR Tab. 10/750mg2022-07-01Drug · Prescription · Approval202202706
- MFDS drugBupensol inj.2022-06-10Drug · Prescription · Notification202202410
- MFDS drugRabenew Tabs 20/500mg2022-01-27Drug · Prescription · Approval202200467
- MFDS drugYungJin Buspirone Tablets 5mg2022-01-18Drug · Prescription · Approval202200672
- MFDS drugYungJin Buspirone Tablets 10mg2022-01-11Drug · Prescription · Approval202200673
- MFDS drugSiDapflo Tab. 10/100mg2022-01-04Drug · Prescription · Approval202200048
- MFDS drugRabenew Tabs. 10/500mg2021-12-31Drug · Prescription · Approval202108204
- MFDS drugXarex 2.5mg Tab.2021-12-24Drug · Prescription · Approval202108105
- MFDS drugPancron F Tab.2021-11-23Drug · OTC · Notification202107591
- MFDS drugXarex 10mg Tab.2021-07-14Drug · Prescription · Approval202105341
- MFDS drugXarex15mg Tab.2021-07-14Drug · Prescription · Approval202105342
- MFDS drugXarex20mg Tab.2021-07-14Drug · Prescription · Approval202105343
- MFDS drugPelps Tab.2021-05-24Drug · Prescription · Approval202104053
- MFDS drugYUNGJIN Teneligliptin Tab. 20mg2021-04-01Drug · Prescription · Approval202102859
- MFDS drugAtorvazin Plus Tab. 10/40mg2021-02-18Drug · Prescription · Approval202101618
- MFDS drugAtorvazin Plus Tab. 10/20mg2021-02-18Drug · Prescription · Approval202101619
- MFDS drugAtorvazin Plus Tab. 10/10mg2021-02-18Drug · Prescription · Approval202101620
- MFDS drugOmaron Mini Soft Cap.2020-12-14Drug · Prescription · Approval202008758
- MFDS drugYungjin Zopiclone Tab. 1mg2020-12-14Drug · Prescription · Approval202008746
- MFDS drugYungjin Zopiclone Tab. 2mg2020-12-14Drug · Prescription · Approval202008747
- MFDS drugYungjin Zopiclone Tab. 3mg2020-12-14Drug · Prescription · Approval202008748
- MFDS drugDapto Inj. 500mg2020-10-14Drug · Prescription · Approval202007027
- MFDS drugDapto Inj. 350mg2020-10-14Drug · Prescription · Approval202007028
- MFDS drugYUNGJIN Melatonin PR Tab. 2mg2020-09-22Drug · Prescription · Approval202006551
- MFDS drugYungjin Dapagliflozin Tab. 10mgRevoked2020-07-23Drug · Prescription · Approval202005356
- MFDS drugYungjin Dapagliflozin Tab. 5mgRevoked2020-07-23Drug · Prescription · Approval202005357
- MFDS drugQutiapine Tab. 50mg2020-06-29Drug · Prescription · Approval202004751
- MFDS drugQutiapine Tab. 12.5mg2020-06-29Drug · Prescription · Approval202004752
- MFDS drugTamrosin SR Tab. 0.4mg2020-04-24Drug · Prescription · Approval202003013
- MFDS drugGaspiran SR Tab. 15mg2020-04-17Drug · Prescription · Approval202002748
- MFDS drugNocid Tab.2020-04-14Drug · OTC · Notification202002642
- MFDS drugYungjin Famotidine Tab. 20mgRevoked2020-02-18Drug · Prescription · Approval202001107
- MFDS drugIvy Pro SyrupRevoked2020-02-04Drug · OTC · Notification202000605
- MFDS drugYunjin Bromelain Enteric Coated Tab. 100mg2019-10-02Drug · OTC · Notification201907042
- MFDS drugTelmirosu Tab. 80/5mgRevoked2019-09-30Drug · Prescription · Approval201906980
- MFDS drugTelmirosu Tab. 40/20mgRevoked2019-09-30Drug · Prescription · Approval201906981
- MFDS drugTelmirosu Tab. 40/10mgRevoked2019-09-30Drug · Prescription · Approval201906982
- MFDS drugTelmirosu Tab. 40/5mgRevoked2019-09-30Drug · Prescription · Approval201906983
- MFDS drugTelmirosu Tab. 80/20mgRevoked2019-09-30Drug · Prescription · Approval201906984
- MFDS drugTelmirosu Tab. 80/10mgRevoked2019-09-30Drug · Prescription · Approval201906985
- MFDS drugAtorvazin Tab. 20mg2019-09-11Drug · Prescription · Approval201906438
- MFDS drugTiasen Inj.2019-07-12Drug · Prescription · Notification201904720
- MFDS drugYungjin Tianeptine Tab.Revoked2019-07-12Drug · Prescription · Approval201904719
- MFDS drugThiocsen Inj.2019-07-09Drug · Prescription · Notification201904638
- MFDS drugZincen Inj.Revoked2019-07-02Drug · Prescription · Notification201904513
- MFDS drugGinkamin Tab. 80mg2019-06-25Drug · OTC · Notification201904346
- MFDS drugYungJin Oseltamivir Suspension Powder 6mg/mLRevoked2019-06-10Drug · Prescription · Approval201903804
- MFDS drugYungjin Cilostazol SR Cap. 100mg2019-05-31Drug · Prescription · Approval201903663
- MFDS drugYungjin Cilostazol SR Cap. 200mg2019-05-31Drug · Prescription · Approval201903664
- MFDS drugYungjin Aminophen Soft Cap. 325mgRevoked2019-05-28Drug · OTC · Notification201903455
- MFDS drugClacid Tab. 500mgRevoked2019-05-23Drug · Prescription · Approval201903343
- MFDS drugDenonex Inj.2019-05-20Drug · Prescription · Approval201903226
- MFDS drugYungjin Fluoxetine Cap. 20mg2019-05-09Drug · Prescription · Approval201903001
- MFDS drugYungjin Fluoxetine cap. 10mg2019-05-02Drug · Prescription · Approval201902843
- MFDS drugYungtracet Semi Tab.Revoked2019-05-02Drug · Prescription · Approval201902837
Showing the 80 most recent of 267 records.
Clinical trials
data.go.kr34 MFDS clinical trial authorisations · 2014–2026 (Bioequivalence 20 · Phase 1 13 · Phase 2 1)
- BioequivalenceYPI-0142026-05-28
2 trial sites
- Phase 1YPG-0432026-03-31
2 trial sites
- Phase 1YPG-0142025-09-18
2 trial sites
- BioequivalenceYPG-0422025-07-17
2 trial sites
- Phase 1YPG-0432025-07-16
2 trial sites
- Phase 1YPG-0402024-10-22
2 trial sites
- Phase 1YPE-0092023-12-06
2 trial sites
- Phase 1YPI-0102023-06-16
2 trial sites
- Phase 1YPI-0052022-12-29
1 trial site
- Bioequivalence영프로마정(프로시클리딘염산염)2022-12-12
2 trial sites
- Bioequivalence영진세파클러시럽2022-12-02
2 trial sites
- Bioequivalence세로파질건조시럽(세프프로질수화물125mg(역가)/5mL)2022-11-28
2 trial sites
Show 22 more
- Bioequivalence펠프스서방정45밀리그램(펠루비프로펜)2022-06-16
2 trial sites
- Bioequivalence펠프스서방정45밀리그램(펠루비프로펜)2022-06-10
2 trial sites
- BioequivalenceYPI-011 20/500mg2022-06-02
2 trial sites
- BioequivalenceYPI-011 10/500mg2022-06-02
2 trial sites
- Bioequivalence세포세틸정(세프포독심프록세틸)2022-05-20
2 trial sites
- Bioequivalence영진세프디토렌피복실세립10%2022-04-18
2 trial sites
- Phase 1YPI-0102021-11-29
2 trial sites
- Bioequivalence아리피진정2밀리그램(아리피프라졸(미분화))2021-10-25
2 trial sites
- Bioequivalence라세카캡슐100mg(라세카도트릴)2021-07-06
2 trial sites
- Bioequivalence자렉스정2.5밀리그램(리바록사반(미분화))2021-01-15
2 trial sites
- Phase 1YPI-0112021-01-05
2 trial sites
- Bioequivalence라세카캡슐100mg(라세카도트릴)2020-09-11
2 trial sites
- Phase 1YPI-0102020-04-20
2 trial sites
- Bioequivalence펠프스정(펠루비프로펜)2020-03-23
2 trial sites
- Bioequivalence영진멀타자핀정15밀리그램(미르타자핀)2019-12-10
2 trial sites
- Bioequivalence자렉스정20밀리그램(리바록사반(미분화))2019-11-27
2 trial sites
- Bioequivalence쿠티아핀정12.5밀리그램2018-12-18
2 trial sites
- Bioequivalence영진설트랄린정 50밀리그램2018-03-08
2 trial sites
- Phase 1YNP-18072017-08-29
1 trial site
- Phase 1KL13332017-02-02
1 trial site
- Phase 2YRA1909(멀꿀잎 물 건조엑스)2015-12-31
23 trial sites
- Phase 1YNP-17072014-01-23
1 trial site
R&D and key agreements
Source: DART corporate disclosure신약 및 개량신약 개발 · Operates a Research HQ (new drug, formulation, analysis, synthesis teams) and Development HQ (RA, planning, IP, PV, clinical teams) conducting new/improved drug development and bioequivalence studies.
Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
KOSDAQ-listed holding company making medical devices and biologics including bone graft rhBMP2 and knee implant TKR.
Spun off and listed in 2013, Chong Kun Dang out-licensed its HDAC6 inhibitor CKD-510 to Novartis in a deal worth about KRW 1.7 trillion.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
KOSPI-listed pharma/biotech company co-developing the autoimmune biologics batoclimab and imeropruvate with partner Immunovant.
KOSPI-listed pharmaceutical company behind the combination drugs Amosartan (hypertension) and Rosuzet (dyslipidemia).
KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.
Hugel is a KOSDAQ-listed pharmaceutical/CDMO company making a botulinum toxin injectable and the hyaluronic acid filler The Chaeum.
KOSDAQ-listed pharmaceutical and healthcare company producing lidocaine anesthetics and the Kynix hyaluronic-acid eye-drop line.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
A pharmaceutical company supplying antifungal and urology drugs to clinics, co-marketing original drugs together with JW Pharmaceutical.
KOSDAQ-listed healthcare company selling the Cissus weight-management ingredient and Sallimbaekseo household products.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition